Search Results for agency_names:"Health and Human Services Department"

The U.S. Department of Health and Human Services (HHS) Office of Minority Health is seeking feedback from Native Hawaiian and Pacific Islander (NHPI) communities and organizations to help develop a new Center for Indigenous Innovation and Health Equity. This center aims to improve health outcomes by focusing on indigenous public health strategies for American Indian, Alaska Native, Native Hawaiian, and Pacific Islander populations. Feedback is requested by March 14, 2021, through the Federal eRulemaking Portal or via email. This is a request for information and does not involve a call for funding proposals or involve financial commitments from the government.

The National Institute of Allergy and Infectious Diseases is holding a closed meeting on April 30, 2025, from 1:00 to 4:00 p.m. This meeting is to review and evaluate contract proposals and will take place via a video-assisted format. The meeting is closed to the public to protect confidential information such as trade secrets and personal data. For more details, contact Dr. Poonam Tewary at the National Institutes of Health.

The Centers for Disease Control and Prevention (CDC) and the Health Resources and Services Administration (HRSA) are holding a public meeting for the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis, and STD Prevention and Treatment (CHACHSPT) on April 12, 2021. This meeting is open to the public and can be accessed through telephone or web conference, with limited lines available. The Committee will discuss topics like HIV testing guidelines and new methods for HIV and HCV testing. The meeting is intended to advise on preventing and controlling these diseases and supporting healthcare services for affected individuals.

The Food and Drug Administration (FDA) has issued an order permanently banning John Warrington Kosolcharoen from working with companies that have approved or pending drug product applications. This decision resulted from his felony conviction for fraudulently selling an unapproved stem cell product, ReGen, and making misleading claims about its safety and effectiveness. Mr. Kosolcharoen was given the chance to challenge the debarment but did not respond in the provided timeframe, leading to a waiver of his right to a hearing on the decision. During his debarment, any business that employs him for related services could also face penalties.

The National Institute on Drug Abuse (NIDA) will hold a closed meeting on May 6, 2025, of the Board of Scientific Counselors. The meeting will be virtual, running from 10:00 a.m. to 4:45 p.m., and is closed to the public to protect personal privacy, as it involves discussions on the qualifications and performance of individual researchers. The meeting will assess various NIDA programs and projects conducted by its members. For inquiries, Megan E. Bollinger and Deon Harvey are the contacts for more information.

The National Advisory Council on Drug Abuse is holding a virtual meeting on May 13, 2025. Part of the meeting will be closed to the public to review grant applications, as it may involve confidential information. The open portion, which will include presentations and Council business, is available to the public and will be broadcast on the NIH's Videocasting website. Individuals needing special accommodations can contact Dr. Gillian Acca in advance, and comments can also be submitted via email.

The document is a notice of a closed meeting by the Centers for Disease Control and Prevention (CDC). It references Gregory Anderson as the contact person for further information, listing his contact details. The notice indicates that Kalwant Smagh, the Director of the Strategic Business Initiatives Unit at the CDC, is authorized to sign Federal Register notices related to meetings and committee activities for the CDC and the Agency for Toxic Substances and Disease Registry. The document also provides details for referencing, including a filing date and a billing code.

The Centers for Disease Control and Prevention (CDC), under the Department of Health and Human Services (HHS), is updating vaccine information materials required by the National Childhood Vaccine Injury Act. These materials must be given to patients or parents before vaccines covered by the National Vaccine Injury Compensation Program (VICP) are administered. The CDC is seeking public comments on these proposed updates, which aim to make the materials clearer and more standardized. The updated materials will provide straightforward explanations about vaccine benefits, risks, and additional safety information, and the public comment period ends on March 12, 2021.

The Food and Drug Administration (FDA) has released a new guidance document for the industry titled “Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act.” This document establishes the conditions for compounding certain drugs and explains the FDA’s current approach while developing a list of bulk drug substances permitted for use. This guidance replaces a previous version from 2017 and provides instructions on submitting comments to the FDA. The guidance clearly states it is not legally binding but shows the FDA's current thinking on this issue.

The National Institute on Minority Health and Health Disparities is holding a closed meeting on March 1, 2021. The meeting is part of the NIMHD Special Emphasis Panel to review and evaluate grant applications for Mentored Career Development Awards. It is being closed to the public to protect confidential information and personal privacy. The meeting will take place virtually at the National Institutes of Health in Bethesda, Maryland.